Yanni Xu - Publications

Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy.

Journal: Acta pharmaceutica Sinica. B

Published: April 16, 2023

HMGB1 released from dead tumor cells after insufficient radiofrequency ablation promotes progression of HCC residual tumor via ERK1/2 pathway.

Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Published: February 09, 2023

Rho GTPase-activating protein 1 promotes hepatocellular carcinoma progression via modulation by CircPIP5K1A/MiR-101-3p.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: February 02, 2023

Innovative signature establishment using lymphangiogenesis-related lncRNA pairs to predict prognosis of hepatocellular carcinoma.

Journal: Heliyon

Published: March 10, 2022

Targeting PI3Kγ/AKT Pathway Remodels LC3-Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 24, 2021

DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration.

Journal: Journal of immunology research

Published: September 25, 2020

Ultrasound Molecular Imaging as a Potential Non-invasive Diagnosis to Detect the Margin of Hepatocarcinoma via CSF-1R Targeting.

Journal: Frontiers in bioengineering and biotechnology

Published: May 10, 2020

Assisting anti-PD-1 antibody treatment with a liposomal system capable of recruiting immune cells.

Journal: Nanoscale

Published: April 11, 2019